Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 12/20 | 0.58 |
| ▸ | MAPK10 | P53779 | 12/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 10/20 | 0.58 |
| ▸ | ROS1 | P08922 | 1/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.56 |
| ▸ | GLS | O94925 | 1/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | PRKCG | P05129 | 1/20 | 0.51 |
| ▸ | PRKCB | P05771 | 1/20 | 0.51 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | PRKACA | P17612 | 1/20 | 0.51 |
| ▸ | PRKACG | P22612 | 1/20 | 0.51 |
| ▸ | PRKACB | P22694 | 1/20 | 0.51 |
| ▸ | PRKCH | P24723 | 1/20 | 0.51 |
| ▸ | PRKCI | P41743 | 1/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3941138 | 0.99 | MAPK8 (0.57) | MAPK8MAPK10MAPK9ROS1RPS6KB1 | |
| SCHEMBL4021165 | 0.86 | ROS1 (0.51) | MAPK8MAPK10MAPK9ROS1RPS6KB1 | |
| SCHEMBL17687045 | 0.85 | ROS1 (0.50) | MAPK8MAPK10MAPK9ROS1RPS6KB1 | |
| Hydrochloric Acid SCHEMBL28231605 | 0.81 | L3MBTL1 (0.64) | MAPK8MAPK10MAPK9ALDH1A1L3MBTL1 | |
| SCHEMBL837578 | 0.81 | TDP1 (0.64) | MAPK8MAPK10MAPK9ROS1RPS6KB1 | |
| SCHEMBL30636331 | 0.81 | TDP1 (0.64) | MAPK8MAPK10MAPK9ROS1RPS6KB1 | |
| Pyridine SCHEMBL28203867 | 0.81 | L3MBTL1 (0.57) | MAPK8MAPK10MAPK9ALDH1A1L3MBTL1 | |
| SCHEMBL29503119 | 0.81 | L3MBTL1 (0.68) | MAPK8MAPK10MAPK9L3MBTL1TDP1 | |
| SCHEMBL709403 | 0.81 | L3MBTL1 (0.68) | MAPK8MAPK10MAPK9L3MBTL1TDP1 | |
| SCHEMBL3785081 | 0.80 | ROS1 (0.56) | MAPK8MAPK10MAPK9ROS1RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247413-B2 | e.g. N-[2-(3-fluorophenyl)ethyl]-N'-isoquinolin-5-ylurea; opioid receptor inhibitor; analgesic, antiinflammatory agent; inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity | ABBOTT LABORATORIES (US) | 2012-08-21 | — | — | US | disclosed |
| EP-1478363-B1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20080214524-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2008-09-04 | — | — | US | disclosed |
| US-7335678-B2 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | ABBOTT LABORATORIES (US) | 2008-02-26 | — | — | US | disclosed |
| WO-2007146838-A2 | SUBSTITUTED PHENYL ACETIC ACIDS AS DP-2 ANTAGONISTS | ICOS CORPORATION (US) | 2007-12-21 | — | — | WO | disclosed |
| CN-1863777-A | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LAB (US) | 2006-11-15 | — | — | CN | disclosed |
| US-7078529-B2 | N-[1-(bi)cycloaliphatic-1H-imidazol-4-yl]-(bi)cycloaliphatic acetamides; central nervous system disorders; enzyme inhibitors of cyclin-dependent kinase-2 and -5, and glycogen synthase kinase-3 | PFIZER INC. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20060149066-A1 | Imidazole derivatives | PFIZER INC | 2006-07-06 | — | — | US | disclosed |
| EP-1660455-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2006-05-31 | — | — | EP | disclosed |
| US-6933311-B2 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040209884-A1 | Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | ABBVIE INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040192750-A1 | Antiproliferative agents; anticancer agents; neurodegenerative agents sexual disorders; antidiabetic agents; urogenital disorders; antidiabetic agents; obesity; muscular disorders; aftertreatment surgery; autoimmune disease | PFIZER INC | 2004-09-30 | — | — | US | disclosed |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2004-08-12 | — | — | US | disclosed |
| US-6756385-B2 | FERTILITY; ANTIDIABETIC AGENTS | PFIZER INC. | 2004-06-29 | — | — | US | disclosed |
| WO-2003070247-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2003-08-21 | — | — | US | disclosed |
| EP-1305295-A1 | IMIDAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030083352-A1 | Synthesis of imidazole intermediates | PFIZER INC. | 2003-05-01 | — | — | US | disclosed |
| US-20020119963-A1 | Imidazole derivatives | PFIZER PRODUCTS INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002010141-A1 | IMIDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214524-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | TRPV1, TMEM109, VIPR1 | MAPK8 1654/4885MAPK10 1182/4885MAPK9 1476/4885 |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | MAPK8 1702/4885MAPK10 1206/4885MAPK9 1437/4885 |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | MAPK8 1732/4885MAPK10 1253/4885MAPK9 1533/4885 |
| US-20040209884-A1 | Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | TRPV1, TMEM109, GPR55 | MAPK8 1645/4885MAPK10 1185/4885MAPK9 1485/4885 |
| US-20030083352-A1 | Synthesis of imidazole intermediates | CDK1, CDK2, CDK3 | MAPK8 428/4885MAPK10 442/4885MAPK9 112/4885 |
| US-20060149066-A1 | Imidazole derivatives | CDK1, CDK3, CKMT1A; CKMT1B | MAPK8 885/4885MAPK10 404/4885MAPK9 560/4885 |
| US-20020119963-A1 | Imidazole derivatives | CDK1, CDK3, CDK2 | MAPK8 786/4885MAPK10 373/4885MAPK9 467/4885 |
| US-20040192750-A1 | Antiproliferative agents; anticancer agents; neurodegenerative agents sexual disorders; antidiabetic agents; urogenital disorders; antidiabetic agents; obesity; muscular disorders; aftertreatment surgery; autoimmune disease | CDK1, CDK3, CDK5 | MAPK8 977/4885MAPK10 342/4885MAPK9 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.